Related references
Note: Only part of the references are listed.FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
Volker Heinemann et al.
BRITISH JOURNAL OF CANCER (2021)
Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies
Dan Aderka et al.
LANCET ONCOLOGY (2019)
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
Ondrej Fiala et al.
ANTICANCER RESEARCH (2019)
Validation of diagnosis codes to identify side of colon in an electronic health record registry
Patricia Luhn et al.
BMC MEDICAL RESEARCH METHODOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
Antonino Grassadonia et al.
JOURNAL OF CANCER (2019)
Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab forMetastatic Colorectal Cancer
Mayada A. Aljehani et al.
JAMA SURGERY (2018)
Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).
Elisa Fontana et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
Julian Walter Holch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Sabine Tejpar et al.
JAMA ONCOLOGY (2017)
Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Heinz -Josef Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto et al.
ONCOLOGIST (2016)
Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The consensus molecular subtypes of colorectal cancer
Justin Guinney et al.
NATURE MEDICINE (2015)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
